Literature DB >> 32335986

Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors.

Yo-Ichi Yamashita1,2, Shinichi Aishima3, Yosuke Nakao2, Tomoharu Yoshizumi1, Hiroaki Nagano1, Tamotsu Kuroki1, Yuko Takami1, Takao Ide1, Masayuki Ohta1, Mitsuhisa Takatsuki1, Atsushi Nanashima1, Fuminori Ishii1, Kenji Kitahara1, Satoshi Iino1, Toru Beppu1, Hideo Baba2, Susumu Eguchi1.   

Abstract

AIM: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a very rare subtype of primary liver carcinoma; therefore, its clinicopathological characteristics have not yet been elucidated in detail. The aim of the study was to reveal the clinicopathological characteristics and prognostic factors of cHCC-CCA after hepatic resection (HR)
METHODS: A total of 124 patients who underwent curative HR for cHCC-CCA between 2000 and 2016 were enrolled in this multi-institutional study conducted by the Kyushu Study Group of Liver Surgery. Clinicopathological analysis was performed from the viewpoint of patient prognosis.
RESULTS: A total of 62 patients (50%) had early recurrence within 1.5 years after HR, including 36 patients (58%) with extrahepatic recurrence. In contrast, just four patients (3%) had late recurrence occurring >3 years after HR. The independent predictors of early recurrence were as follows: des-gamma carboxyprothrombin >40 mAU/mL (odds ratio 26.2, P = 0.0117), carbohydrate antigen 19-9>37 IU/l (odds ratio 18.0, P = 0.0200), and poorly differentiated HCC or CCA (odds ratio 11.2, P = 0.0259).
CONCLUSIONS: Half of the patients with cHCC-CCA had early recurrence after HR. Preoperative elevation of des-gamma carboxyprothrombin or carbohydrate antigen 19-9 and the existence of poorly differentiated components of HCC or CCA in resected specimens are predictors of its early recurrence.
© 2020 The Japan Society of Hepatology.

Entities:  

Keywords:  combined hepatocellular-cholangiocarcinoma; early recurrence; predictors of early recurrence

Year:  2020        PMID: 32335986     DOI: 10.1111/hepr.13507

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  6 in total

1.  The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery.

Authors:  Jiake Xu; Shaochun Li; Ye Feng; Jie Zhang; Youduo Peng; Xiaohong Wang; Hongwei Wang
Journal:  Cancer Manag Res       Date:  2022-05-23       Impact factor: 3.602

2.  Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma.

Authors:  Tao Wang; Wanxiang Wang; Jinfu Zhang; Xianwei Yang; Shu Shen; Wentao Wang
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

3.  Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Xuejiao Chen; Dawei Rong; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  J Oncol       Date:  2021-12-10       Impact factor: 4.375

4.  Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Nomogram Based on Ultrasonographic Features and Clinical Indicators.

Authors:  Yanling Chen; Qing Lu; Weibin Zhang; Jiaying Cao; Yi Dong; Wenping Wang
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

5.  Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study.

Authors:  Yijun Wu; Hongzhi Liu; Jianxing Zeng; Yifan Chen; Guoxu Fang; Jinyu Zhang; Weiping Zhou; Yongyi Zeng; Jingfeng Liu
Journal:  World J Surg Oncol       Date:  2022-02-28       Impact factor: 2.754

6.  Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma: A propensity score matched study.

Authors:  Wen-Qiang Wang; Jian Li; Bin-Yong Liang; Xing Lv; Rong-Hua Zhu; Jin-Lin Wang; Zhi-Yong Huang; Shu-Hong Yang; Er-Lei Zhang
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.